Study: T-1249 benefits those with resistance to Fuzeon
BY Advocate.com Editors
September 17 2003 11:00 PM ET
Study data presented Monday at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy show that Roche and Trimeris's second-generation experimental fusion inhibitor, T-1249, can reduce the HIV viral loads of patients who have developed resistance to the companies' first fusion inhibitor, Fuzeon. Data from a Phase I/II study of the experimental drug showed that it was effective in significantly reducing the viral loads of 73% of patients who developed resistance to Fuzeon. No serious drug-related side effects were reported by the study volunteers. "The results from this study of T-1249 demonstrate that fusion inhibitors constitute an expanding class of anti-HIV drugs with the potential to be used sequentially," said Dani Bolognesi, CEO at Trimeris. Next up are Phase II clinical trials, which will begin in 2004.
- WATCH: The 12 Gayest Holiday Spectaculars Ever!
- Op-ed: What I Didn't Learn in Catholic School
- Bryan Singer Announces News for Next X-Men Film
- Salvation Army 'Does Not Consider Homosexual Orientation a Sin'
- These Couples Prove Love Is Love
- Redbox Picks Up Bridegroom Despite Rule Against Documentaries
- Politics Gay Former Republican Congressman Condemns Interparty Discrimination 2 hours 5 min ago
- World News Putin Tightens Grip on Kremlin-Run News Agencies 2 hours 9 min ago
- Film Redbox Picks Up Bridegroom Despite Rule Against Documentaries 2 hours 18 min ago
- Travel Super Seniors of the Palm Springs Follies Prepare for the End 2 hours 23 min ago
- Film Bryan Singer Announces News for Next X-Men Film 2 hours 23 min ago
- Acceptance Matters WATCH: We Wish Every Coming Out Got a Hug-a-Thon 2 hours 32 min ago
- Marriage Equality Antigay Think Tank Could Use a Copy Editor 2 hours 36 min ago